

## **Press release**

---

Lyon, Tuesday, July 8, 2020

### **NUTRISENS GROUP TAKES A NEW STEP IN ITS EUROPEAN DEVELOPMENT**

At the beginning of 2018, NUTRISENS acquired VEGENAT HEALTHCARE, a company specialising in clinical nutrition. After its first acquisition in Spain, NUTRISENS has just finalized 100% of IPCO's integration. Based in Extremadura and employing 38 persons, IPCO will consolidate the group's industrial and logistical for its clinical nutrition products, particularly thanks to its enriched formula products (proteins, minerals, vitamins...).

Created in 2010 from three companies (Tonus Line, Proalim, Edé Ruy) held by EVOLEM, NUTRISENS has been combining internal growth, establishment of subsidiaries as well as external growth in France and in Europe for 10 years. NUTRISENS has become a European benchmark in specialised nutrition : medical nutrition (malnutrition, dysphagia...), specific diets (salt and allergen-free food...) and wellness approach.

Favouring taste and the pleasure of eating, NUTRISENS has based its model on innovation process within its ecosystem, by calling on the services of cooks, dietiticians, R&D engineers and experts in specialised nutrition. The group offers more than 900 products manufactured in four European production sites distributed to hospitals, care homes and private homes.

Thanks to this new acquisition, NUTRISENS has increased its turnover to more than € 85M, 40% of which is generated internationally, and now employs close to 340 persons.

#### About EVOLEM

EVOLEM, the majority shareholder of NUTRISENS, is a family office, created in 1997 and owned 100% by Bruno ROUSSET, the founder of APRIL GROUP. Its entrepreneurial approach to investing is based on long term strategic vision, shared with the management and with no exit horizon, in order to accompany the development of reference players in specific sectors.

EVOLEM employs 19 persons and has accompanied 87 companies with more than € 200M invested since its creation. EVOLEM represents today more than 5 300 jobs and € 630M in aggregate revenue.

In the context of majority transactions, the Evolem team invests in companies with turnover between € 10M and € 80M and operating in niche consolidation markets, with the objective of enabling them to move from small to intermediate size (€ 100M to € 150M sales) both through organic and external growth.

Having completed 66 external growth operations (22 of which were international), Evolem has solid experience in carrying out build-up operations for its divisions, both in identifying and approaching potential targets, as well as in the negotiation and execution of operations.

More information on : [www.evolem.com](http://www.evolem.com)

**Contact** -> Peggy DESOUTTER : [peggy.desoutter@evolem.com](mailto:peggy.desoutter@evolem.com)

Tél / +33 (0)4 72 68 98 00